Immutep reports Q2 cash receipts from customers A$8,000

During the quarter, Immutep (IMMP) continued to advance its clinical trial programs for efti and for IMP761.R The company said, “The Company is well funded with a strong cash, cash equivalent and term deposit balance as at 31 December 2024 of approximately A$159.26 million in total, which gives Immutep an expected cash reach to the end of CY2026” The A$159.26M total balance consists of: a cash and cash equivalent balance of A$73.89M and bank term deposits totalling A$85.37M, which have been recognised as short-term investments due to having maturities of more than 3 months and less than 12 months. In Q2 FY25, cash receipts from customers were A$8k. The net cash used in G&A activities in the quarter was A$566k, compared to A$961k in Q1 FY25. Payments to Related Parties comprises Non-Executive Directors’ fees and Executive Directors’ remuneration of A$344k. The net cash used in R&D activities during the quarter was A$16.2M, compared to A$9.5M to Q1 FY25. The increase is mainly due to the increased level of clinical trial activities especially the commencement of the phase III TACTI-004 clinical trial. Payments for staff costs were A$2.5M in the quarter compared to A$2.8M in Q1 FY25. Total net cash outflows used in operating activities in the quarter were A$19M compared to A$8.6M in Q1 FY25.